Back to search

Article

First-in-Human Study of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix

2025-10-08

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Antibodies against the SARS-CoV-2 spike receptor-binding domain provided effective COVID-19 treatment until resistant variants emerged. GB-0669 is a half-life extended monoclonal antibody optimized using artificial intelligence, targeting the conserved spike S2 stem helix, a region with limited selective pressure from natural infection-or vaccine-induced antibody responses....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
91bc68b8-9c9b-5549-84ca-4069baed5281
DOI
10.1101/2025.10.07.25337449
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
First-in-Human Study of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem HelixDOI 10.1101/2025.10.07.25337449
Select a neighboring publication to make it the new centre.